Jobs
Properties
Automarket
Databank
EasyBanking
Search
Categories
Companies
People
Sectors
Topics
Business
Events
Conferences
Local trade exhibitions
International trade exhibitions
Professional
Training
Executive training
Trade
Missions
Incoming
Outgoing
Weekly
Newsletter
View latest issue
Subscribe
Update my subscription
Unsubscribe
SUBMIT INFO
News
Conferences
Exhibitions
Tenders
Training
Missions
Search
Categories
Financial
Markets
Business
Events
Trade
Missions
Business
Research
Calculation
Tools
Weekly
Newsletter
SUBMIT INFO
CHAMPION OF THE DAY
LEADERS NEWS
Medical innovation
for diabetes by Benta
More than $10 million allocated for R&D
Benta Pharma Industries (BPI), a local manufacturer of pharmaceuticals, has achieved promising results of an innovation it’s working on in collaboration with Vanderbilt and Harvard universities.
The innovation enables the implantation of a human pancreas islets inside a human body without the need for immunosuppressive therapy, which makes the body less likely to reject the transplanted organ.
“Implanting subcutaneous human pancreas technology has been available for a long time, but Benta’s innovation is implantation without any need for immunosuppressive drugs,” said Bernard Tannoury, Chairman.
Benta’s efforts center on the reduction of external insulin and the elimination of immunosuppressive drugs for patients with diabetes, with the goal of eventually eradicating the disease. It conducted experiments and studies on animals in its laboratories as well as in the US.
“We have received approval for conducting clinical trials on humans,” Tannoury said.
BPI has been working on the innovation for five years. “More than $10 million were allocated for developing the product between Lebanon and US,” said Tannoury.
The donation of the human pancreas for the clinical trials is being supervised by the National Organization for Organ and Tissues Donation and Transplantation (NOD-LB) in collaboration with the Ministry of Public Health.
The clinical trial on human will take one-year-and-a-half to be completed. Additional time will be needed before the product is commercially ready. “We aim to market the product globally,” Tannoury said.
The pilot clinical trials on diabetes will be the first to be conducted locally and in the Arab region. It will be steered by the company's biotechnology division, in cooperation with doctors and researchers in the field of endocrinology, diabetes, applied sciences and Encapsulife, an American company based in the United States.
Reported by Rania Ghanem
Your browser does not support iframes.
Date Posted:
Oct 19, 2018
Your browser does not support inline frames
ABOUT
ADVERTISE
SUBMIT INFO
RSS
CONTACT US
©
2021 by InfoPro sal. All Rights Reserved